发明授权
US08961950B2 Neoadjuvant treatment of cancer with proleukin 有权
新辅助治疗癌细胞白介素

Neoadjuvant treatment of cancer with proleukin
摘要:
Low doses of IL-2 are administered locally and neo-adjuvantly to patients with early stages of the disease. This will result in local high concentrations of IL-2 within the relevant tumor draining lymph nodes. Patients with only early stages of disease will be more responsive to immunotherapy with the expectation of improved survival of patients compared to current therapy standards.
公开/授权文献
信息查询
0/0